

## Limited Submission Funding Opportunities – updated 11/17/23

*Please be aware that any grant that brings in less than 20% in indirect costs (IDC) will need to be supplemented up to the 20% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.*

*For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 20% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.*

*This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.*

*For further questions, please contact ECOR at [ecor@mgch.harvard.edu](mailto:ecor@mgch.harvard.edu)*

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

### Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to [ecor@mgch.harvard.edu](mailto:ecor@mgch.harvard.edu). In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. *Name of the Principal Investigator with appropriate contact information*
2. *A descriptive title of the potential application*
3. *Brief description of the project*
4. *Brief description of why you specifically should be selected to receive institutional nomination for this award*

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at [ecor@mgch.harvard.edu](mailto:ecor@mgch.harvard.edu).

### CURRENT OPPORTUNITIES

#### 1. **Advancing Research Careers (ARC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 – Clinical Trial Not Allowed)**

The NIH Research Education Program supports research education activities in the mission areas of the NIH. The overarching goal of this ARC UE5 program is to support educational activities that encourage individuals from diverse backgrounds, for example those from groups underrepresented in the biomedical and behavioral sciences (see [Notice of NIH's Interest in Diversity](#)), to pursue further studies or careers in research. The overarching goal of this UE5 program is to support educational activities that encourage individuals from diverse backgrounds, for example those from groups underrepresented in the biomedical and behavioral sciences (see [Notice of NIH's Interest in Diversity](#)), to pursue further studies or careers in research.

## Limited Submission Funding Opportunities – *updated 11/17/23*

To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on:

- ***Courses for Skills Development***
- ***Mentoring Activities***

Applications are encouraged from organizations that have:

- Experience enhancing scientific communication and networking among early-career biomedical researchers;
- An established record of providing professional development and networking activities for future biomedical researchers; and
- A demonstrated commitment to enhancing the diversity of the biomedical research workforce.

The program provides support for well-designed courses for skills development and mentoring activities to prepare cohorts of ARC predoctoral F99 fellows and K00 postdoctoral scholars to transition into and succeed in mentored postdoctoral research, positioning them to advance in impactful careers in the biomedical research workforce that typically require postdoctoral training (e.g., academic research and teaching at a range of institution types, industry or government research).

Recipient organizations must provide career development and mentoring activities aligned with and appropriate for the disciplinary backgrounds and career goals of scholars supported through the ARC F99/K00 program.

**MGH LOI Deadline: 11/29/23**

Sponsor Application Deadline: 1/29/24

[Learn more](#)

### **2. NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed) – NEW!**

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

*This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs ([PAR-23-287](#) or [PAR-23-288](#)).*

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs ([PAR-23-286](#), [PAR-23-287](#), and/or [PAR-23-288](#)).

## Limited Submission Funding Opportunities – *updated 11/17/23*

**MGH LOI Deadline: 12/12/23**

NIH Application Deadline: 2/14/24

[Learn more](#)

### **3. NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required) – NEW!**

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO ([PAR-23-286](#)).

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs ([PAR-23-286](#), [PAR-23-287](#), and/or [PAR-23-288](#)).

**MGH LOI Deadline: 12/12/23**

NIH Application Deadline: 2/14/24

[Learn more](#)

### **4. NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Basic Experimental Studies with Humans Required) – NEW!**

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

## Limited Submission Funding Opportunities – *updated 11/17/23*

This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO ([PAR-23-286](#)).

This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in [NOT-OD-18-212](#) as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs ([PAR-23-286](#), [PAR-23-287](#), and/or [PAR-23-288](#)).

**MGH LOI Deadline: 12/12/23**

NIH Application Deadline: 2/14/24

[Learn more](#)

### 5. The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required) – NEW!

This notice of funding opportunity (NOFO) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN) and contribute to the network's capacity to respond to urgent public health needs. The National Institute on Drug Abuse (NIDA) intends to continue to develop and test interventions for addressing the wide spectrum of substance use problems via collaborative partnerships among NIDA, clinical research investigators, community representatives, healthcare providers, and healthcare institutions.

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available [PEDP guidance material](#).

**MGH LOI Deadline: 1/10/24**

NIH LOI Deadline: 2/13/24

NIH Application Deadline: 3/13/24

[Learn more](#)